Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
RX

NASDAQ · RXST

RxSight, Inc.

Healthcare · Medical - Devices

$5.96

Up+$0.06 (+1.01%)

Updated Sep 12, 2026, 12:59 AM

SID Score

3.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
539.04M
P/E ratio
-16.56
Dividend yield
0.00%
52-week range
$4.48 – $13.22
Volume
667.39K
Avg. volume
777.3K

Price performance

RXST price history

1M range · 19 trading sessions · Daily adjusted prices

RXST closed at $5.96 after 19 trading sessions, down 13.50% for the selected period.

Last close
$5.96
Period change
-13.50%
Period low
$5.96
Period high
$7.33
Daily close
View OHLC price history
RXST OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$6.26$6.325$5.89$5.96667.39K
Sep 9, 2026$6.41$6.655$6.265$6.331.21M
Sep 8, 2026$6.28$6.47$6.05$6.45734.19K
Sep 4, 2026$6.47$6.63$6.34$6.375561.3K
Sep 3, 2026$7.11$7.11$6.48$6.54605.39K
Sep 2, 2026$6.96$7.345$6.909$7.03778.87K
Sep 1, 2026$7.28$7.44$6.955$6.99988.92K
Aug 31, 2026$7.05$7.36$7.00$7.331.29M
Aug 28, 2026$6.59$7.06$6.55$7.05663.4K
Aug 27, 2026$6.36$6.69$6.27$6.61580.12K
Aug 26, 2026$6.36$6.61$6.185$6.381.72M
Aug 25, 2026$6.23$6.41$6.14$6.40366.35K
Aug 24, 2026$6.26$6.55$6.184$6.26480.56K
Aug 21, 2026$6.10$6.31$6.00$6.251.54M
Aug 20, 2026$6.09$6.245$5.945$6.09663K
Aug 19, 2026$6.37$6.66$6.095$6.16622.53K
Aug 18, 2026$6.38$6.67$6.26$6.37712.54K
Aug 17, 2026$6.80$6.87$6.385$6.48657.08K
Aug 14, 2026$7.04$7.095$6.87$6.89488.39K

Latest RXST news

The latest Smart Investors Daily articles mentioning RXST.

Stock researchCompany · Overview

RXST research

Overview

Company profile and research snapshot.

Company profile

RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$10.00
Implied upside
—
Analysts
—
RXST recent ratings
DateFirmRatingTarget
Aug 10, 2026StifelHold—
Aug 6, 2026UBSNeutral—
Jul 7, 2026NeedhamBuy—
Jul 7, 2026B of A SecuritiesUnderperform—
May 7, 2026Wells FargoEqual-Weight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 26, 2026

RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference

ALISO VIEJO, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. ET in Boston, Massachusetts. A live and archived webcast of the presentation will be available on the Company’s investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providin

Yahoo · Aug 13, 2026

Could Alcon (ALC) and RxSight (RXST)’s Partnership Reshape the Future of Cataract Surgery?

Two ophthalmic technology leaders, Alcon Inc. (NYSE:ALC) and RxSight, Inc. (NASDAQ:RXST), earlier on July 6 entered into a strategic collaboration that highlights the evolving landscape of cataract and refractive surgery. The companies announced a non-exclusive pact to co-develop post-operatively adjustable pseudophakic intraocular lenses (PCIOLs). By pairing RxSight’s proprietary light-adjustable technology, which allows eye surgeons to […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By